AMARIN CORP PLC appointed Adam Berger and Geraldine Murphy to Board of Directors. Lars Ekman and Patrick OSullivan to Retire from Amarin Board at year-end. New Independent Directors Bring Significant International Experience in Healthcare and Finance.

Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months. Amarin Continues Active Board Refreshment Program. Amarin Corporation plc announced the appointment of Adam Berger and Geraldine Murphy as independent members of the company's Board of Directors, effective immediately.

The Company also announced that, as part of their planned retirement, Lars Ekman, M.D., Ph.D and Patrick OSullivan, directors of Amarin since 2008 and 2011, respectively, will retire from the Board, effective at the end of the year. With these changes, the Amarin Board will remain at eight directors, seven of whom are independent and five of whom have been appointed in the past year as part of the Board replenishment process which seeks to add international experience to support the company's global expansion efforts. About Adam Berger: Mr. Berger currently serves as Managing Partner of Three Peaks Partners, where he provides financial advisory services to healthcare companies.

Mr. Berger has advised a wide range of corporate M&A, including both domestic and international transactions in the healthcare space. He has worked with and advised CEOs, Boards of Directors, and Board committees on various aspects of transactions, including deal strategy and tactics, deal structure, terms, and the exploration of strategic alternatives. Prior to Three Peaks Partners, Mr. Berger served as Managing Director and Head of Healthcare M&A at Wells Fargo Securities.

He also served as the Chairman of Wells Fargos Investment Banking Opinion Committee, leading a group of senior M&A bankers with responsibility for reviewing the firms most sensitive M&A transactions, including determining the firms valuation policies and guidelines and evaluating the possible issuance of fairness opinions. Prior to joining Wells Fargo in 2011, Mr. Berger led the Healthcare M&A effort at Citigroup and was head of Leerinks M&A group, after working for many years in Salomon Brothers M&A group. Mr. Berger has advised many leading companies in the healthcare industry.

About Geraldine Murphy: Ms. Murphy an Irish National - currently serves as Founder and Managing Partner of Evolution-Partners, where she provides strategic counsel to executive teams as they evolve during periods of transformation and significant change to support delivering revenue and profit growth. Ms. Murphy is an accomplished leader in the biopharmaceutical industry with a demonstrated ability to deliver outstanding results in complex, highly regulated environments. She possesses more than 30 years of pharmaceutical executive experience across core business areas including manufacturing, supply chain, P&L management, commercial strategy development and business transformation.

With a background in science and business and with a deep understanding of governance and regulatory environments in pharma, Ms. Murphy has demonstrated strong collaboration and influencing skills through involvement in high-profile pan-EU projects requiring consensus and alignment across multiple stakeholders. Ms. Murphy has led international operations across U.K., Europe, Canada, and Australia, delivering significant revenue and profit growth while building key partnerships with regulatory, customer and employee stakeholders. Ms. Murphy is a past member of the Irish Pharmaceutical Healthcare Association (2009-2012) and negotiating team who secured a landmark 4-year supply agreement with the Department of Health.

She is a past member of the Association of British Pharmaceutical Industries (ABPI) DoH supply agreement reference group (2013).